Hangzhou Yuhong Pharmaceutical Technology

Hangzhou Yuhong Pharmaceutical Technology is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation small molecule drugs for oncology and metabolic disorders. The company utilizes a proprietary structure-based drug discovery platform to address high-value, challenging targets such as USP1, HPK1, and SOS1. Its lead program, YH01, is a highly selective USP1 inhibitor currently in Phase 1 clinical development for patients with advanced solid tumors, particularly those with DNA damage response deficiencies. Headquartered in Hangzhou, China, Yuhong Pharma was founded by experienced drug discovery experts and is backed by leading life science investors including Lilly Asia Ventures and Qiming Venture Partners.